Updates

August 29, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE LTD. National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block, Bandra Kurla Complex, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 SCRIP CODE: 543748 SYMBOL: AARTIPHARM Dear Sir/Madam, Sub: Business Responsibility and Sustainability Report for the Financial Year 2025-26 Ref: Regulation 34(2)(f) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”). In continuation to our intimation dated August 29, 2026 regarding the Annual Report for the Financial Year 2025-26, along with Notice of the 7th Annual General Meeting, and pursuant to Regulation 34(2)(f) of the Listing Regulations, we are submitting herewith the Business Responsibility and Sustainability Report for the Financial Year 2025-26. The Business Responsibility and Sustainability Report is also available on the website of the Company at: https://www.aartipharmalabs.com/business-responsibilty-report Please take the same on your records. Thanking you, Yours faithfully, For AARTI PHARMALABS LIMITED Jeevan Mondkar COMPANY SECRETARY AND LEGAL HEAD ICSI M. NO. A22565 Encl.: a/a Annual Report 2025-26 BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT SECTION A: GENERAL DISCLOSURES I. DETAILS OF THE LISTED ENTITY 1. Corporate Identity Number (CIN) of the Company L24100GJ2019PLC110964 2. Name of the Company Aarti Pharmalabs Limited 3. Year of Incorporation November 22, 2019 4. Registered office address Plot No. 22/C/1 & 22/C/2, 1st Phase, G.I.D.C. Vapi, Valsad, Vapi, Gujarat, India, 396195 5. Corporate office address Aarti Pharmalabs Limited Embassy Park 247, Tower C, 401, 4th Floor, LBS Marg, Vikhroli (W), Mumbai, India - 400 083 6. E-mail id info@aartipharmalabs.com 7. Telephone +91 022-69436100 8. Website www.aartipharmalabs.com 9. Financial year for which reporting is being done April 01, 2025 to March 31, 2026 10. Name of the Stock Exchange(s) where shares are a. BSE Limited listed b. National Stock Exchange of India Limited 11. Paid-up capital ` 45,32,88,755 12. Name and contact details of the person who may Smt. Hetal Gogri Gala be contacted in case of any queries on the BRSR Vice Chairperson & Managing Director report Tel: +91 022-69436100 Email: infoapi@aartipharmalabs.com 13. Reporting boundary Standalone basis 14. Name of assessment or assurance provider While BRSR Core assurance is not mandatory for the 15. Type of assessment or assurance obtained Company, APL is proactively undertaking it to demonstrate our commitment to transparency and responsible business practices. We will conduct a Type 2 Moderate Assurance of our Sustainability Report and BRSR Core indicators in accordance with AA1000AS standards, and these efforts will be formally reflected in our Sustainability Report. II. PRODUCTS/SERVICES 16. Details of business activities (accounting for 90% of the turnover): S. Description of main activity Description of business activity % of total turnover No. contributed 1. Manufacturing of Development of Active Pharmaceutical 100% Pharmaceuticals and Ingredients (API) and New Chemical Entities Nutraceuticals (NCE), API intermediates, Regulatory Starting Materials (RSM), Basic Starting Materials, Key Building Blocks, and Xanthine Derivatives for use in clinical testing and commercial production. 17. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): S. Product/Service NIC Code % of total turnover No. contributed 1 API (Active Pharmaceutical Ingredients), Pharmaceutical Intermediates, 210 51 New Chemical Entities 2 Xanthine Derivatives 1104 49 Business Responsibility & Sustainability Report III. OPERATIONS 18. Number of locations where plants and/or operations/offices of the entity are situated: Location Number of plants* Number of offices Total National 15* 3 18 International 0 0 0 * Number of plants includes our 3 R&D facilities. 19. Markets served by the entity: a. Number of locations – This refers to locations where goods were transported to during the financial year, however the consumption of final product & even customer footprint is larger. Locations Number National (No. of states) 25 International (No. of countries) 51 b. What is the contribution of exports as a percentage of the total turnover of the entity? The Company has a global presence with exports accounting for approximately 55.93% of its total turnover. c. A brief on types of customers A arti Pharmalabs Limited serves a broad array of B2B clients in regulated and non-regulated sectors globally. The Company’s customer portfolio features international pharmaceutical innovators and generic drug producers seeking premium APIs, advanced intermediates, and CDMO expertise, specifically for stringent markets like the United States, Japan, and the European Union. Beyond pharmaceuticals, APL provides specialty ingredients, including xanthine derivatives, to major food, beverage, and nutraceutical firms worldwide. The entity also supports manufacturers in the agrochemical, polymer, plastics, and dye and pigment industries by supplying high-purity chemical intermediates, monomers, and performance additives. These enduring client partnerships are anchored in APL’s commitment to rigorous regulatory standards, extensive backward integration, and the capability to provide dependable, scalable, and bespoke solutions that meet precise industry requirements. IV. EMPLOYEES 20. Details as of March 31, 2026 a. Employees and workers (including differently abled) S. No. Particulars Total (A) Male Female No. (B) % (B/A) No. (C) % (C/A) EMPLOYEES 1. Permanent (D) 1899 1773 93.36 126 06.64 2. Other than permanent (E) 134 104 77.61 30 22.39 3. Total employees (D + E) 2033 1877 92.33 156 07.67 WORKERS 1. Permanent (F) 522 522 100 0 0 2. Other than permanent (G) 1663 1635 98.32 28 01.68 3. Total workers (F + G) 2185 2157 98.72 28 01.28 b. Differently abled Employees and workers: S. No. Particulars Total (A) Male Female No. (B) % (B/A) No. (C) % (C/A) DIFFERENTLY ABLED EMPLOYEES 1. Permanent (D) 1 1 100 0 0 2. Other than permanent (E) 0 0 0 0 0 3. Total differently abled employees (D + E) 1 1 100 0 0 DIFFERENTLY ABLED WORKERS 1. Permanent (F) 1 1 100 0 0 2. Other than permanent (G) 0 0 0 0 0 3. Total differently abled workers (F + G) 1 1 100 0 0 STATUTORY REPORTS Annual Report 2025-26 21. Participation/inclusion/representation of women Total (A) No. and percentage of Females No. (B) % (B/A) Board of Directors 12 4 33.3 Key Management Personnel (other than BoD) 2 0 0 22. Turnover rate for permanent employees Particulars FY 2025-26 (%) FY 2024-25 (%) FY2023-24 (%) Male Female Total Male Female Total Male Female Total Permanent Employee 23.80 12.99 23.45 3.93 2.11 3.82 9.17 8.25 9.02 Permanent Workers 5.29 0 5.31 0.67 0 0.67 4.77 0 4.77 V. HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES (INCLUDING JOINT VENTURES) 23. (a) Names of holding/subsidiary/associate companies/joint ventures S. Name of the holding/subsidiary/ Indicate whether % of shares Does the entity indicated No. associate companies/joint holding/Subsidiary/ held by listed at column A, participate in ventures (A) Associate/Joint entity the Business Responsibility Venture initiatives of the listed entity? (Yes/No) 1 Aarti Pharmachem Limited Subsidiary 100% No 2 Aarti USA Inc. Subsidiary 100% No 3 Ganesh Polychem Limited Joint Venture 50% No VI. CSR DETAILS 24. (i) Whether CSR is applicable as per section 135 of Companies Act, 2013: Yes (ii) Turnover : ` 17,975,517,198 (iii) Net worth : ` 19,740,942,000 VII. TRANSPARENCY AND DISCLOSURES COMPLIANCES 25. Complaints/grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct (NGRBC) The Company’s key stakeholders include investors, customers, employees, value chain partners/suppliers and community besides governments/regulatory authorities. Stakeholder Grievance Redres [Showing first 8,000 characters — download PDF for full document]